kras g-12c inhibitor 5

5-LOX inhibitor (1-(sec-Butyl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one) is one of the impurities of itraconazole, a selective LOX-5 inhibitor.

1-[4-(2,3-dihydro-1,4-benzodioxine-6-sulfonyl)piperazin-1-yl]-2-(6-methyl-1-benzofuran-3-yl)ethan-1-one Yes An organic structural unit.

PKM2 inhibitor G is a inhibitor of pyruvate kinase.

C-Met inhibitor D9 is a c-Met kinase inhibitor.

GSK-3 Inhibitor 5 (4-Cyanophenacyl bromide) is a ketone derivative that is used as an intermediate in pharmaceuticals and organic synthesis, and inhibits glycogen synthase kinase 3 (GSK-3).

GSK-3β inhibitor 12 is a selective GSK-3β inhibitor.GSK-3β inhibitor 12 inhibits 49.11% of 25 μM GSK-3β activity and 37.11% of 50 μM GSK-3β activity.GSK-3β inhibitor 12 can be used for the study of Parkinson's in the presence of lipopolysaccharide induction.

ACHE Inhibitor 12 inhibited acetylcholinesterase with an IC50 value of 0.38 µM.

5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE targets PLK1.

MMP-12 Inhibitor is a selective inhibitor of MMP-12 with IC50s of 2, 160, 320, and 22.3 nM for human, mouse, rat, and sheep MMP-12.

ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor (IC50 : 15.3 nM) that reduces the level of CCl4-induced hepatic fibrosis and has anti-hepatic fibrosis effects,.

KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor with potential anticancer and antitumor activity, inhibits cancer cell proliferation, and can be used in the study of lung cancer.

C-Myc Inhibitor 7, serving as both a c-Myc inhibitor and a multi-target protein degrader, effectively degrades proteins c-MYC, CK1α, GSPT1, and IKZF1/2/3 across various tumor cell types. It holds potential for research into diseases associated with high c-Myc expression, including cancer, cardiovascular and cerebrovascular conditions, and viral infections.

KRas G12C inhibitor 1 is a compound that inhibits KRas G12C.

KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.

Tuberculosis Inhibitor 12, an oxadiazole derivative, effectively inhibits Mycobacterium tuberculosis, demonstrating inhibition rates of 82% and 78% at a concentration of 20 μM on 7H9-Tw-OADC media, respectively [1].

3α-Acetoxyurs-5:12-dien-24-oic acid, a natural compound, is isolatable from Boswellia sacra Fluckiger [1].

Protein kinase G inhibitor-2 exhibits antibacterial, antiviral, and antitumor activities.

KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor for potential treatment in cancer.

KRAS G12D Inhibitor 17 (example 8), a quinazoline-linked (4R)-4-hydroxy-L-prolinamide compound, acts as a proteolysis targeting chimera (PROTAC) [1], specifically inducing degradation of the G12D-mutation KRAS protein.

7-Methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine is a building block.1It has been used in the synthesis of PI3K inhibitors. 1.Scott, W.J., Hentemann, M.F., Rowley, R.B., et al.Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: Identification of copanlisib (BAY 80-6946)ChemMedChem.11(14)1517-1530(2016)

Compound 1059182-21-6 features a cyclic structure characterized by a nitrogen atom occupying an apex (corner) within the heterocycle. Its molecular scaffold integrates aromatic properties due to the presence of a conjugated system, while the inclusion of hydroxyl (-OH) groups confers reactive potential for subsequent modification. Additionally, a halogenated component, specifically a bromine atom, is attached to the aromatic ring, enhancing its propensity for undergoing further synthetic transformations.

Protein kinase G inhibitor-1 is a potent Protein kinase G inhibitor, IC50= 0.9 uM.

KRAS G12C inhibitor 56, a powerful inhibitor of SOS1 with an inhibitory concentration (IC50) of 1.6 nM, holds promise for use in cancer research.

5(S),12(S)-DiHETE is a natural bioactive lipid derived from arachidonic acid . It is synthesized by glycogen-induced rabbit peritoneal polymorphonuclear leukocytes (PMNLs) incubated with AA. 5(S),12(S)-DiHETE can be produced by successive oxygenation of AA by 5-lipoxygenase (5-LO) in platelets and 12-LO in leukocytes. It can also be synthesized from 12(S)-HETE by 5-LO, in the presence of 5-LO activating protein (FLAP), activated with calcium ionophore. 5(S),12(S)-DiHETE is an epimer of leukotriene B4 that is weakly chemotactic for PMNL.

WRN Inhibitor 5 (Example 157), a cyclic vinyl sulfone-based compound, serves as an inhibitor of Werner Syndrome ATP-dependent helicase enzyme (WRN). It is utilized in cancer research [1].

KRAS G12D inhibitor 5 is a KRAS G12D inhibitor for the potential treatment of pancreatic cancer.

KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that shows anti-tumor activity in cellular assays, and the family inhibits tumor growth.

KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D.

5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite is a potent nucleic acid analog belonging to the class of modified antisense oligonucleotide [1].

KRAS G12C mutant protein inhibitor A-1 can be used in studies about Ras.

KRAS G12C inhibitor 1R can be used in studies about Ras.

Kras binder 12 can be used in studies about Ras.

KRAS G12C inhibitor 18 is a potent, orally active compound that inhibits KRAS G12C and exhibits anti-tumor activities.

5'-ODMT cEt G Phosphoramidite Amidite is a powerful nucleic acid analog that demonstrates exceptional safety and potent antisense activity, as evidenced in studies [1] [2].

3-(9-Chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)benzeneacetamide inhibits multidrug resistance protein (MRP1).

KRAS inhibitor FB9 can be used in studies about Ras.

Boc-MLF (TFA) is a specific antagonist of formyl peptide receptor (FPR) and also inhibits signaling through FPRL1 at higher concentrations.

KRAS G12C inhibitor 5 is a KRas G12C inhibitor.

Bromodomain Inhibitor-12 Edisylate (example 303) serves as a bromodomain inhibitor applicable to autoimmune and inflammatory disease research [1].

mTOR inhibitor-12 (Compound 11), a selective, brain-penetrant mTOR inhibitor, exhibits no genotoxicity risk and is utilized in research pertaining to central nervous system (CNS) diseases [1].

5'-O-Benzoyl-2'-O,4'-C-methyleneuridine is a Nucleoside Derivative - LNA related nucleoside; Protected nucleoside with NH2/OH open.

Topoisomerase II inhibitor 5 (Compound E24) is a DNAtopoisomerase II inhibitor with anticancer effects.

KRAS inhibitor-14 is a potent inhibitor of KRAS G12C (IC50: 0.249 μM). KRAS inhibitor-14 exhibited p-ERK inhibition in MIA PaCA-2, A549 cells with IC50s of 1.12, >33.3 μM, respectively. KRAS inhibitor-14 has potential to be investigated in pancreatic, colorectal and lung cancers.

5'-O-Benzoyl-3'-O-(4-methoxybenzoyl)-2'-O,4'-C-methyleneuridine is a Nucleoside Derivative - LNA-related nucleoside.

Nucleoside Derivatives - 5’-Modified nucleosides; 6-Modified purine nucleosides; N-Methylated nucleosides

KRAS G12C Inhibitor 37, a potent inhibitor of KRAS G12C, targets the Ras family of proteins, crucial for intracellular signaling related to growth and development. This compound holds potential for research into cancers mediated by KRAS G12C.

KRAS G12D Inhibitor 10 is a potent agent targeting the KRAS G12D mutation, a variant in the Ras protein family crucial for cellular growth and development. This compound shows promise for investigating cancers mediated by KRAS G12D.

KRAS G12C inhibitor 20 is a KRAS G12C inhibitor.

PI3K/mTOR Inhibitor-12, a potent and selective orally active inhibitor, exhibits IC50 values of 0.06 nM for PI3Kα and 3.12 nM for mTOR, indicating significant antitumor activity with reduced liver toxicity [1].

C-Myc Inhibitor 8 is an effective compound for cancer research, inhibiting cell viability across a range of cancer types and demonstrating growth suppression in human prostate and lung cancers within mouse models. This inhibitor specifically targets the c-Myc pathway, showcasing its potential utility in oncological studies.